Core Viewpoint - A class action has been filed against Charming Medical, Limited (NASDAQ: MCTA) for allegedly engaging in a fraudulent stock promotion scheme that misled investors and artificially inflated its stock price [1][2][3] Allegations - The complaint alleges that Charming Medical failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [2] - Insiders and/or affiliates reportedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2] - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that were driving the stock price [2] Stock Price Surge - In the weeks leading up to November 12, 2025, Charming's share price increased from the initial public offering price of $4.00 to a peak of $29.36 per share, despite a lack of fundamental news justifying such a rise [3] - Investigations revealed that the stock was subject to an illicit promotion scheme that created a buying frenzy among retail investors through sensational but unfounded claims made by impersonators posing as legitimate financial advisors [3] - Trading of Charming's stock was halted by the SEC on November 12, 2025, and remains suspended due to the company's failure to provide required information to regulators [3] Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit papers to the court by February 17, 2026, and do not need to participate in the case to be eligible for recovery [4] - Absent class members can choose not to take action while still being eligible for potential recovery [4] Legal Representation - All representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]
MCTA CLASS ACTION ALERT: Robbins LLP Urges Charming Medical, Limited Stockholders with Large Losses to Contact the Firm About Leading the Class Action